Lipum AB (publ) has published the interim report Q1 for the period January-March 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – March 2025Other operating income: 492 KSEK (94)Result after financial items: -19 010 KSEK (-9 313)Cash and cash equivalents as of March 31: [...]
Lipum AB (publ) announces the completion and publication of the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116. The study investigated single ascending doses (SAD) and multiple doses (MD) of SOL-116 in healthy volunteers, as well as a single dose in patients with mild rheumatoid arthritis (RA), and the findings [...]
The previous date for the Annual General Meeting for the financial year 2024 was May 14, 2025, but is now postponed to June 16, 2025. ContactsOla Sandborgh, CEOola.sandborgh@lipum.se+46 72 218 80 21Web: www.lipum.se About UsLipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory [...]
Lipum AB (publ) has published the Q4 interim and year-end report for 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – December 2024Other operating income: 911 KSEK (165)Result after financial items: -55 516 KSEK (-37 178)Cash and cash equivalents as of December 31: 6 [...]
Lipum AB (publ) announces the completion of its phase I clinical trial (LPM-116-001) evaluating SOL-116, with positive results. The study confirmed SOL-116’s favourable safety, tolerability, and predictable pharmacokinetics, supporting a once-monthly dosing regimen. Furthermore, exploratory analyses confirmed that SOL-116 effectively suppressed BSSL in both healthy volunteers and rheumatoid arthritis (RA) patients. These findings mark a [...]
Lipum AB (publ) announces that the company, together with the Norwegian company Age Labs AS, has received a grant from Eurostars. The companies will establish knowledge and technology for the diagnosis and treatment of rheumatoid arthritis with the drug candidate SOL-116. Eurostars finances 50% of the project budget of approximately EUR 1.9 million. The goal [...]
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2025. In accordance with the decision at the Annual General Meeting 2024, the three largest shareholders in terms of voting rights are entitled to appoint a representative to constitute the Nomination Committee for the Annual General Meeting 2025 together with the Chairman [...]
Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from its first-in-human clinical trial of SOL-116 at the American College of Rheumatology (ACR) Annual Meeting 2024. SOL-116, a pioneering humanized monoclonal antibody developed by Lipum, specifically targets Bile Salt-Stimulated Lipase (BSSL), a protein linked to chronic [...]
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Ola Sandborgh comments: “Time flies and suddenly autumn is here. But as you know, time flies when you have a lot to do and [...]
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in the ongoing clinical phase 1 study. The drug candidate SOL-116 is a humanized antibody that will provide safer and more effective treatment of inflammatory diseases by blocking a previously overlooked [...]